Innovative Cancer Treatment LBL-024 Shows Promise in Phase II Results
June 7, 2024, 3:38 pm
Location: United States, Virginia, Alexandria
Employees: 501-1000
Founded date: 1964
The groundbreaking cancer research presented at the 2024 ASCO Annual Meeting showcased Leads Biolabs' innovative cancer treatment, LBL-024. This bispecific antibody has shown outstanding results in phase II trials, particularly in patients with extrapulmonary neuroendocrine carcinomas (EP-NEC) who have failed previous chemotherapy treatments.
EP-NEC is a rare and aggressive disease that often goes undetected until it has spread to other parts of the body, leading to poor prognosis. The lack of approved treatments for this malignancy highlights the urgent need for novel therapeutic approaches, like LBL-024.
The results of the phase II trial demonstrated the safety and efficacy of LBL-024 monotherapy, with promising anti-tumor effects observed in patients with advanced malignant tumors. The drug showed good safety profile, with mild liver toxicity being the most common adverse event. Additionally, LBL-024 exhibited robust anti-tumor activities across a wide therapeutic dose range in EP-NEC patients.
The data presented at the ASCO Annual Meeting showed an objective response rate (ORR) of 37.5% and disease control rate (DCR) of 50.0% in second-line EP-NEC patients treated with LBL-024. Furthermore, patients with PD-L1 negative expression also showed a significant response to the treatment, indicating the potential benefits of LBL-024 regardless of PD-L1 status.
The positive efficacy data of LBL-024 has paved the way for the drug's continued development in patients with EP-NEC. A single-arm pivotal study has been approved to further evaluate the drug's potential as a standard treatment option for patients who have progressed on second-line therapy.
Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, emphasized the significance of LBL-024's selection for oral presentation at ASCO, highlighting the drug's differentiated and innovative development strategy. Dr. Xiaoqiang Kang, founder and CEO of Leads Biolabs, reiterated the company's commitment to innovation and addressing unmet medical needs through the development of novel antibody drugs.
LBL-024, a bispecific antibody targeting PD-L1 and 4-1BB, has shown promising results in activating T cells and enhancing the immune response against tumor cells. This unique mechanism of action sets LBL-024 apart from existing monoclonal antibodies and positions it as a potential first-in-class treatment for EP-NEC.
Leads Biolabs, a clinical-stage biotechnology company based in Nanjing, is dedicated to developing novel antibody drugs for oncology and other diseases with high unmet medical needs. With a robust pipeline of innovative molecules, Leads Biolabs aims to provide safe, effective, and accessible treatments for patients worldwide.
In conclusion, the phase II results of LBL-024 presented at the 2024 ASCO Annual Meeting demonstrate the drug's potential as a promising treatment option for patients with EP-NEC. The innovative approach and strong efficacy signals of LBL-024 underscore the importance of continued research and development in the field of cancer immunotherapy.
EP-NEC is a rare and aggressive disease that often goes undetected until it has spread to other parts of the body, leading to poor prognosis. The lack of approved treatments for this malignancy highlights the urgent need for novel therapeutic approaches, like LBL-024.
The results of the phase II trial demonstrated the safety and efficacy of LBL-024 monotherapy, with promising anti-tumor effects observed in patients with advanced malignant tumors. The drug showed good safety profile, with mild liver toxicity being the most common adverse event. Additionally, LBL-024 exhibited robust anti-tumor activities across a wide therapeutic dose range in EP-NEC patients.
The data presented at the ASCO Annual Meeting showed an objective response rate (ORR) of 37.5% and disease control rate (DCR) of 50.0% in second-line EP-NEC patients treated with LBL-024. Furthermore, patients with PD-L1 negative expression also showed a significant response to the treatment, indicating the potential benefits of LBL-024 regardless of PD-L1 status.
The positive efficacy data of LBL-024 has paved the way for the drug's continued development in patients with EP-NEC. A single-arm pivotal study has been approved to further evaluate the drug's potential as a standard treatment option for patients who have progressed on second-line therapy.
Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, emphasized the significance of LBL-024's selection for oral presentation at ASCO, highlighting the drug's differentiated and innovative development strategy. Dr. Xiaoqiang Kang, founder and CEO of Leads Biolabs, reiterated the company's commitment to innovation and addressing unmet medical needs through the development of novel antibody drugs.
LBL-024, a bispecific antibody targeting PD-L1 and 4-1BB, has shown promising results in activating T cells and enhancing the immune response against tumor cells. This unique mechanism of action sets LBL-024 apart from existing monoclonal antibodies and positions it as a potential first-in-class treatment for EP-NEC.
Leads Biolabs, a clinical-stage biotechnology company based in Nanjing, is dedicated to developing novel antibody drugs for oncology and other diseases with high unmet medical needs. With a robust pipeline of innovative molecules, Leads Biolabs aims to provide safe, effective, and accessible treatments for patients worldwide.
In conclusion, the phase II results of LBL-024 presented at the 2024 ASCO Annual Meeting demonstrate the drug's potential as a promising treatment option for patients with EP-NEC. The innovative approach and strong efficacy signals of LBL-024 underscore the importance of continued research and development in the field of cancer immunotherapy.